Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:INBX NASDAQ:KALV NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$10.25-2.4%$9.18$5.65▼$11.31$366.31M1.07257,334 shs155,511 shsINBXInhibrx Biosciences$97.10-3.6%$103.65$19.51▼$155.29$1.48B3.41320,558 shs499,744 shsKALVKalVista Pharmaceuticals$27.00$26.74$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$19.07-0.4%$18.45$5.95▼$62.75$1.41B1.041.34 million shs1.20 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-1.78%-2.33%+20.69%+61.79%+23.97%INBXInhibrx Biosciences+3.72%+6.33%+15.79%+50.08%+449.05%KALVKalVista Pharmaceuticals0.00%0.00%+0.19%+40.11%+79.28%MLTXMoonLake Immunotherapeutics+1.43%-1.55%+6.98%+2.96%-59.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$10.25-2.4%$9.18$5.65▼$11.31$366.31M1.07257,334 shs155,511 shsINBXInhibrx Biosciences$97.10-3.6%$103.65$19.51▼$155.29$1.48B3.41320,558 shs499,744 shsKALVKalVista Pharmaceuticals$27.00$26.74$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$19.07-0.4%$18.45$5.95▼$62.75$1.41B1.041.34 million shs1.20 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-1.78%-2.33%+20.69%+61.79%+23.97%INBXInhibrx Biosciences+3.72%+6.33%+15.79%+50.08%+449.05%KALVKalVista Pharmaceuticals0.00%0.00%+0.19%+40.11%+79.28%MLTXMoonLake Immunotherapeutics+1.43%-1.55%+6.98%+2.96%-59.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 2.71Moderate Buy$15.4050.24% UpsideINBXInhibrx Biosciences 2.33Hold$150.0054.48% UpsideKALVKalVista Pharmaceuticals 2.22Hold$33.2523.15% UpsideMLTXMoonLake Immunotherapeutics 2.41Hold$24.2126.98% UpsideCurrent Analyst Ratings BreakdownLatest FENC, KALV, MLTX, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MLTXMoonLake Immunotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $29.006/16/2026INBXInhibrx Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/22/2026FENCAdherex Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $16.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/1/2026KALVKalVista Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$37.00 ➝ $27.004/30/2026KALVKalVista Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$51.00M7.01N/AN/A$1.04 per share9.86INBXInhibrx Biosciences$1.30M1,095.74N/AN/A$0.55 per share176.55KALVKalVista Pharmaceuticals$1.43M1,008.07N/AN/A$2.71 per share9.96MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$9.74M-$0.29N/A11.14N/A-17.12%-43.87%-11.35%8/13/2026 (Estimated)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%8/13/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)Latest FENC, KALV, MLTX, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A5/14/2026Q1 2026FENCAdherex Technologies-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$40.86 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A6.986.78INBXInhibrx Biosciences12.586.466.46KALVKalVista Pharmaceuticals8.185.175.10MLTXMoonLake Immunotherapeutics0.398.608.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%INBXInhibrx Biosciences82.46%KALVKalVista PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies10.73%INBXInhibrx Biosciences18.26%KALVKalVista Pharmaceuticals4.30%MLTXMoonLake Immunotherapeutics12.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1034.89 million31.14 millionOptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionableKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableFENC, KALV, MLTX, and INBX HeadlinesRecent News About These CompaniesInsider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $956,933.25 in StockJuly 5 at 5:01 AM | americanbankingnews.comMoonLake Immunotherapeutics' CFO Sells 39K SharesJuly 3, 2026 | finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $956,933.25 in StockJuly 3, 2026 | insidertrades.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, Leerink Partners Analyst SaysJuly 1, 2026 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis SuppurativaJune 30, 2026 | finance.yahoo.comMoonLake Immunotherapeutics - Ordinary Shares - Class AJune 26, 2026 | money.usnews.comMoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label ExpansionJune 26, 2026 | seekingalpha.comHow Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On OfferingJune 25, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces $200 Million Public OfferingJune 25, 2026 | tipranks.comGuggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)June 24, 2026 | theglobeandmail.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comMLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest developmentJune 24, 2026 | msn.comCaitong International Asset Management Co. Ltd Cuts Holdings in MoonLake Immunotherapeutics $MLTXJune 24, 2026 | marketbeat.comMoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsJune 23, 2026 | quiverquant.comQMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | globenewswire.comMoonLake Immunotherapeutics: Label Upside Drives The Next Leg HigherJune 23, 2026 | seekingalpha.comMLTX stock clocks best day in over 6 months — what’s driving the investor optimism?June 23, 2026 | msn.comMoonLake Immunotherapeutics Announces Proposed Public OfferingJune 22, 2026 | globenewswire.comWhy Is MoonLake Immunotherapeutics Stock Soaring Monday?June 22, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFENC, KALV, MLTX, and INBX Company DescriptionsAdherex Technologies NASDAQ:FENC$10.25 -0.25 (-2.38%) Closing price 04:00 PM EasternExtended Trading$10.26 +0.01 (+0.05%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Inhibrx Biosciences NASDAQ:INBX$97.10 -3.65 (-3.62%) Closing price 04:00 PM EasternExtended Trading$97.42 +0.32 (+0.32%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.KalVista Pharmaceuticals NASDAQ:KALV$27.00 0.00 (0.00%) As of 06/12/2026KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$19.07 -0.08 (-0.42%) Closing price 04:00 PM EasternExtended Trading$19.07 0.00 (0.00%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
